Our broad portfolio consists of multiplex panels that allow you to choose, within the panel, analytes that best meet your needs. On a separate tab you can choose the premixed cytokine format or a single plex kit.
Cell Signaling Kits & MAPmates™
Choose fixed kits that allow you to explore entire pathways or processes. Or design your own kits by choosing single plex MAPmates™, following the provided guidelines.
The following MAPmates™ should not be plexed together:
-MAPmates™ that require a different assay buffer
-Phospho-specific and total MAPmate™ pairs, e.g. total GSK3β and GSK3β (Ser 9)
-PanTyr and site-specific MAPmates™, e.g. Phospho-EGF Receptor and phospho-STAT1 (Tyr701)
-More than 1 phospho-MAPmate™ for a single target (Akt, STAT3)
-GAPDH and β-Tubulin cannot be plexed with kits or MAPmates™ containing panTyr
.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Select A Species, Panel Type, Kit or Sample Type
To begin designing your MILLIPLEX® MAP kit select a species, a panel type or kit of interest.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Species
Panel Type
Selected Kit
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
96-Well Plate
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
Add Additional Reagents (Buffer and Detection Kit is required for use with MAPmates)
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
This item has been added to favorites.
The Product Has Been Added To Your Cart
You can now customize another kit, choose a premixed kit, check out or close the ordering tool.
We measured the levels of mutant huntingtin (mtHtt) and total huntingtin (tHtt) in blood leukocytes from Prospective Huntington At-Risk Observational Study (PHAROS) subjects at 50% risk of carrying the Huntington disease mutation using a homogeneous time-resolved fluorescence (HTRF) assay to assess its potential as a biomarker.Peripheral blood mononuclear cells from consenting PHAROS subjects were analyzed by HTRF using antibodies that simultaneously measured mtHtt and tHtt. mtHtt levels were normalized to tHtt, double-stranded DNA, or protein and analyzed according to cytosine-adenine-guanine repeat length (CAGn), demographics, predicted time to clinical onset or known time since clinical onset, and available clinical measures.From 363 assayed samples, 342 met quality control standards. Levels of mtHtt and mt/tHtt were higher in 114 subjects with expanded CAG repeats (CAG ≥ 37) compared with 228 subjects with nonexpanded CAG repeats (CAG less than 37) (p less than 0.0001). Analysis of relationships to predicted time to onset or to phenoconversion suggested that the HTRF signal could mark changes during the Huntington disease prodrome or after clinical onset.The HTRF assay can effectively measure mtHtt in multicenter sample sets and may be useful in trials of therapies targeting huntingtin.
Document Type:
Reference
Product Catalog Number:
MAB2166
Product Catalog Name:
Anti-Huntingtin Protein Antibody, a.a. 181-810, clone 1HU-4C8
Considerable controversy surrounds the question of whether or not nerve growth factor (NGF) or a related nerve growth-promoting factor is present in serum. Recently, supporting its role as a local neuronotrophic factor, the presence of NGF in glial cells and its production in target tissues of NGF-responsive neurons were demonstrated [Rush: Nature 312:364-367, 1984; Heumann, Korsching, Scott, Thoenen: EMBOJ 3:3183-3189, 1984; Shelton and Reichardt: Proc Natl Acad Sci USA 81:7952-7955, 1984]. At the same time, the concept that NGF may play a role as a humoral factor has been questioned, since careful analyses of serum with specific and sensitive radioimmunoassays [Suda, Barde, Thoenen: Proc Natl Acad Sci USA 75:4042-4046, 1978; Korsching and Thoenen; Proc Natl Acad Sci USA 80:3513-3516, 1983; Furukawa, Kamo, Furukawa, Akazawa, Satoyoshi, Itoh, Hayashi: J Neurochem 40:734-744, 1983] as well as bioassays [Skaper and Varon: Exp Neurol 76:655-665, 1982] have not confirmed earlier reports [Levi-Montalcini and Booker; Proc Natl Acad Sci USA 46:373-391, 1960; Banks, Banthorpe, Charlwood, Pearce, Vernon: Nature 246:503-504, 1973; Hendry: Biochem J 128:1265-1272, 1972] on NGF's representation in serum. In this study serum from mouse, rat, and man was analyzed with an in vitro bioassay system which employs sensory neurons from chicken embyro dorsal root ganglia and which allows the measurement of NGF concentrations as low as 0.8 pM. It was found that sera from all these species contained neuronotrophic activity (S-NGF). The target cell spectrum as well as characteristic parameters of the neuronal growth response of S-NGF and of NGF were identical. S-NGF of mouse serum was completely inhibitable by polyclonal and monoclonal antibodies to mouse submandibular gland beta NGF. On polyacrylamide isoelectric focussing gels mouse and human S-NGF could be recovered from the same position as NGF as well as from the region where alpha 2-macroglobulin and serum albumin focused. In newborn and adult male and female mice basal S-NGF levels were equivalent to 10-50 pM NGF. A fraction of the serum samples of male mice showed elevated S-NGF levels. The incidence of high S-NGF levels was more frequent in NMRI and C57BL/6 males than in BALB/c males. Following sialectomy of male mice only basal S-NGF levels were observed up to 5 weeks after the operation. This indicates that although the submandibular gland may contribute to S-NGF levels in serum under certain conditions that appeared to be stress related, it cannot be the only source of S-NGF.